AstraZeneca opens 4,500-person obesity trial for elecoglipron
A 4,500-person trial is the first piece of a roughly 25,000-person Phase 3 program for elecoglipron, but no results on weight loss, safety or heart and kidney outcomes are available yet.
AstraZeneca has begun enrolling a 4,500-person Phase 3 master protocol for elecoglipron, its experimental treatment for obesity and overweight, in people with and without type 2 diabetes, according to the study's federal trial registry listing [1].
That obesity study, registered as NCT07667803, anchors a Phase 3 program that also includes five diabetes trials under the Eluminate name and two outcomes trials, Elevate-HF and Elevate-CKD. Together, the program aims for roughly 25,000 participants [1][2][3].
Elecoglipron is still an investigational drug. It is not an approved medicine, and no results from these trials have been released.
What the trials are testing
The obesity study is titled "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM" [1]. A master protocol uses one overarching design to run related studies under a single structure, which lets a sponsor test more than one question or more than one group of people at the same time. The listing covers adults with obesity or overweight, including those who also have type 2 diabetes [1].
One of the program's outcome trials is registered as NCT07761117, "A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF" [2]. That trial is set up to compare elecoglipron with a placebo and measure cardiovascular outcomes in adults with heart failure with preserved ejection fraction or heart failure with mildly reduced ejection fraction. A third registry entry, NCT07753993, is listed as part of the same elecoglipron program [3].
What is not known
How much weight elecoglipron helps people lose has not been reported. How the drug is taken, its dose, its side effects, and how it compares with medicines already on the market have not been disclosed. The registry entries do not include study results, and AstraZeneca has not said when it expects the program to report findings.
Why it matters for patients
Phase 3 is the last stage of testing before a company can ask the FDA to approve a drug, and the size of this program means answers about benefits and risks will come from thousands of people rather than a few hundred. That is the kind of evidence regulators weigh when they decide whether a new obesity treatment can be sold.
The heart failure and kidney trials are measuring whether the drug changes the course of those conditions, not just body weight. If it does, that would be a different kind of evidence than weight loss alone, and the results would apply to people whose health risks go beyond obesity itself.
Nothing changes today for people already taking an approved obesity or diabetes medicine. This development involves an investigational drug, and no data have been published. For people who have obesity or overweight, with or without type 2 diabetes, the registry entries spell out who can and cannot join each study [1][2][3].
What happens next
Enrollment in the 4,500-person obesity master protocol is under way [1]. The two outcomes trials, Elevate-HF and Elevate-CKD, are part of the same roughly 25,000-participant program [2][3]. Completion dates and expected reporting timelines for the program have not been reported, and outcome trials of this size typically take several years to produce results.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.